NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

[1]  F. Zhan,et al.  Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma , 2015, Oncotarget.

[2]  H. Einsele,et al.  Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study , 2015 .

[3]  F. Zhan,et al.  ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma , 2014, Leukemia.

[4]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[5]  L. Suva,et al.  Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. , 2010, Cancer research.

[6]  R. Sanderson,et al.  Heparanase: busy at the cell surface. , 2009, Trends in biochemical sciences.

[7]  B. Barlogie,et al.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.

[8]  David R Williams,et al.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.

[9]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[10]  John Crowley,et al.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.

[11]  Kyungjin Kim,et al.  Suppression of Nek2A in mouse early embryos confirms its requirement for chromosome segregation , 2004, Journal of Cell Science.

[12]  A. Fry,et al.  Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. , 2003, Molecular biology of the cell.

[13]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[14]  B. Ness,et al.  The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell , 1993, The Journal of experimental medicine.